These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2042 related items for PubMed ID: 14981104

  • 1. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.
    J Clin Oncol; 2004 Mar 15; 22(6):1055-62. PubMed ID: 14981104
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group.
    N Engl J Med; 2002 May 23; 346(21):1616-22. PubMed ID: 12023993
    [Abstract] [Full Text] [Related]

  • 3. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group.
    J Clin Oncol; 2008 Mar 01; 26(7):1093-7. PubMed ID: 18195327
    [Abstract] [Full Text] [Related]

  • 4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.
    Gynecol Oncol; 2005 May 01; 97(2):457-67. PubMed ID: 15863145
    [Abstract] [Full Text] [Related]

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

  • 6. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
    J Clin Oncol; 2003 May 01; 21(9):1675-81. PubMed ID: 12721241
    [Abstract] [Full Text] [Related]

  • 7. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.
    Clin Breast Cancer; 2007 Dec 01; 7(11):875-82. PubMed ID: 18269778
    [Abstract] [Full Text] [Related]

  • 8. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.
    J Natl Cancer Inst; 2004 Jul 21; 96(14):1094-8. PubMed ID: 15265971
    [Abstract] [Full Text] [Related]

  • 9. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.
    N Engl J Med; 2001 Jul 19; 345(3):159-64. PubMed ID: 11463009
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.
    Ann Surg; 2010 Mar 19; 251(3):488-92. PubMed ID: 20134318
    [Abstract] [Full Text] [Related]

  • 11. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.
    Cancer; 2003 Jan 01; 97(1):1-11. PubMed ID: 12491499
    [Abstract] [Full Text] [Related]

  • 12. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.
    Obstet Gynecol; 2006 Sep 01; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [Abstract] [Full Text] [Related]

  • 13. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA.
    J Clin Oncol; 2004 Jun 15; 22(12):2328-35. PubMed ID: 15197194
    [Abstract] [Full Text] [Related]

  • 14. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA.
    J Clin Oncol; 2005 Oct 20; 23(30):7491-6. PubMed ID: 16234515
    [Abstract] [Full Text] [Related]

  • 15. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group, Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C.
    Breast Cancer Res Treat; 2007 Oct 20; 105(2):221-8. PubMed ID: 17245541
    [Abstract] [Full Text] [Related]

  • 16. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Australian Ovarian Cancer Study Management Group.
    J Natl Cancer Inst; 2008 Nov 05; 100(21):1519-29. PubMed ID: 18957670
    [Abstract] [Full Text] [Related]

  • 17. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D, Kuntz KM, Garber JE, Weeks JC.
    N Engl J Med; 1997 May 15; 336(20):1465-71. PubMed ID: 9148160
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [Abstract] [Full Text] [Related]

  • 19. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
    Pierce L.
    Semin Radiat Oncol; 2002 Oct 01; 12(4):352-61. PubMed ID: 12382193
    [Abstract] [Full Text] [Related]

  • 20. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.
    Cancer J Sci Am; 2000 Oct 01; 6(1):13-20. PubMed ID: 10696733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.